BioMedNewsBreaks – Brain Scientific Inc. (BRSF) Announces Partnership with Dalmore Group for Upcoming Offering

October 27, 2020 10:52:47

Brain Scientific (OTCQB: BRSF), a neurology-focused medical device and software company, is partnering with the Dalmore Group, a member of the Financial Industry Regulatory Authority, Inc. (“FINRA”) and the Securities Investor Protection Corporation (“SIPC”), for a regulation A+ offering. Based in New York, the Dalmore Group has an active presence in the Reg A+ equity funding space and is one of the most active broker-dealers in the world for Regulation A+ offerings; the company has served as broker-dealer on more than 50 such offerings in the past year. Brain Scientific recently unveiled its exclusive NeuroCap(TM) device, a next-generation, 19-channel, hospital-grade disposable EEG headset. The new NeuroCap features Velcro materials for advanced adhesion during EEG testing. Studies indicate that more than 80% of patients hospitalized for COVID-19 are developing neurological symptoms. Consequently, Brain Scientific anticipates the new EEG cap will be used in a growing number of medical facilities across the United States. “We are delighted to get the Dalmore Group on board and to be able to offer our stock to a much wider pool of investors,” said Brain Scientific chairman Boris Goldstein in the press release. “Our partners are experienced with Regulation A+ offerings and are licensed in all 50 states. With our recent product development and new product launches, we feel the need to extend the proposed Regulation A+ Offering to attract additional investors, which we believe we can better accomplish by working with Dalmore.”

To view the full press release, visit

About Brain Scientific Inc.

Brain Scientific is a commercial-stage healthcare company with two FDA-cleared products providing next-generation solutions to the neurology market. The company’s smart diagnostic devices and sensors simplify administration, shorten scan time and cut costs, allowing clinicians to make rapid decisions remotely and bridge the widening gap in access to neurological care. To learn more about the company, visit

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:

BioMedWire (BMW)
San Francisco, California
415.949.5050 Office

BioMedWire is part of the InvestorBrandNetwork